Morphinum Hydrochloricum Teva

Quick links

Choose a section

Quick links to important sections

Advertisements

Morphinum Hydrochloricum Teva

Advertisements
Advertisements

Overview of Morphinum Hydrochloricum Teva

Property Description
Active Ingredient Morphine (as Hydrochloride or Sulfate salt)
Form Solution for injection, Sustained-release tablet
Pharmacological Class Opioid Analgesic
Common Use Management of severe pain (e.g., palliative care)
Origin Naturally derived opiate (from Papaver somniferum)

Morphinum Hydrochloricum Teva is a potent prescription-only analgesic medication manufactured by Teva, belonging to the Opioid Analgesic pharmacological class. The preparation is a single-ingredient product whose core active substance is morphine, which classifies the drug as an opiate due to its natural source. It is fundamentally defined by its powerful ability to alleviate severe pain that has not responded adequately to non-opioid pain relievers.

What Type of Medicine is Morphinum Hydrochloricum Teva?

This medicine is formally classified as a full opioid agonist because its active ingredient, morphine, binds to and completely activates the mu-opioid receptors in the central nervous system. The specific formulation under the Teva brand is utilized in established pain management protocols, such as providing relief in palliative care settings. Morphine serves a critical role in pain management within clinical health systems.

Composition and Available Forms

The therapeutic effect is derived from the morphine molecule, which is administered as a salt, such as Morphine Hydrochloride or Morphine Sulfate. Morphine is a naturally derived compound, being the most abundant of the opium alkaloids extracted from the Papaver somniferum plant. The key differentiating feature of the Teva product line is the availability of both the injection solution for rapid parenteral administration in acute settings and sustained-release tablets for stable, long-term oral pain control, thereby supporting treatment strategies for severe, persistent pain.

What is the General Purpose of Morphine Analgesics?

The overarching general therapeutic purpose of this medication is to provide relief from severe pain by centrally modulating the patient's subjective perception of pain. This action is reserved for managing pain that is intense, whether acute or chronic, and cannot be adequately managed by less potent pain relievers.

Regulatory References

  1. Essential Medicines List
Advertisements

What side effects are possible with Morphinum Hydrochloricum Teva?

Official Classification of Possible Side Effects

The safety profile of morphine, the active ingredient in Morphinum Hydrochloricum Teva, is formally documented by regulatory authorities (e.g., EMA, FDA) through frequency classification and system-organ grouping. The most serious documented safety concern is Respiratory Depression, which is dose-dependent and categorized as a serious adverse reaction.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by incidence according to regulatory standards:

Frequency Examples (System-Organ Class)
Very Common Constipation, Somnolence (Gastrointestinal, Nervous System)
Common Nausea, Vomiting, Dizziness, Headache (Gastrointestinal, Nervous System)
Uncommon Bradycardia, Hypotension, Urticaria (Cardiovascular, Skin)
Frequency Not Known Tolerance, Physical Dependence, Withdrawal Syndrome (Psychiatric, Nervous System)

Safety Considerations for Specific Populations

Official labeling addresses altered safety profiles for certain patient groups. Older adults (geriatric patients) are noted to have increased sensitivity to central nervous system effects, including respiratory depression and sedation. Patients with renal impairment carry a risk of metabolite accumulation, which can prolong the opioid effects and increase the risk of adverse reactions.

Exposure-Related Safety Patterns

The development of tolerance (reduced responsiveness) and physical/psychological dependence is formally associated with the repeated and prolonged administration of morphine, as explicitly stated in regulatory documentation. This is a key safety component of long-term therapy.

Advertisements

Overdose and Emergency Response

Overdose of Morphinum Hydrochloricum Teva is formally classified in regulatory labeling as a potentially life-threatening medical emergency primarily defined by severe central nervous system (CNS) and respiratory depression. Documented clinical manifestations include profound drowsiness, stupor, and coma. The official profile emphasizes the primary severe risk is progression to life-threatening respiratory depression and eventual circulatory depression.

Documented Presentations and Severe Outcomes

Classification Official Statements
Documented Manifestations Severely depressed breathing, pinpoint pupils (miosis), low blood pressure (hypotension), weak pulse, and cyanosis.
Severe Outcomes Respiratory arrest, cardiac arrest, death. Accidental ingestion of even a single dose by a child can result in a fatal overdose.

Mandated Emergency Actions and Management

Official guidance mandates seeking immediate medical attention by calling emergency services or the poison control center upon recognizing the symptoms. Immediate help is required when the patient exhibits slowed breathing, long pauses between breaths, difficulty breathing, seizure, or an inability to be woken up.

Naloxone is specified as the opioid antagonist used for reversal. Management includes symptomatic and supportive treatment, such as securing the airway, administering oxygen, and continuous monitoring of vital signs. Procedures like activated charcoal or gastric lavage are described as potential supportive interventions in official overdose protocols. Patients with severe renal or hepatic impairment are noted to have an increased risk of toxicity.

Advertisements

Therapeutic Uses of Morphinum Hydrochloricum Teva

What Morphinum Hydrochloricum Teva Treats: Main Uses and Benefits

The primary therapeutic uses of this medication involve the relief of severe pain in situations where additional symptomatic support is required.

Morphinum Hydrochloricum Teva is considered relevant across several therapeutic domains. It is generally applied for symptoms associated with chronic intractable pain, acute pain crises, including those following major surgery or trauma, and severe pain from conditions like myocardial infarction or cancer. Furthermore, it is also relevant for assisting with the distressing symptom of severe breathlessness (dyspnea) in supportive therapeutic domains like palliative care.

The goal is to support stable pain management. This application may assist with improving comfort and helps ease the overall symptom load during periods of heightened symptoms in advanced stages of certain conditions. This contributes to improved day-to-day comfort and helps patients cope more steadily with difficult episodes.


Quick Fact: Support for Symptoms of Severe Discomfort

Clinical Focus Symptom Category Patient Benefit
Chronic Intractable Pain Severe, persistent physical discomfort Supports stable pain management
Acute Crises Intense, temporary pain spikes Provides supportive symptomatic assistance
Palliative Care Severe pain and breathlessness Helps ease overall symptom load

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The eligibility for Morphinum Hydrochloricum Teva is strictly defined by regulatory guidelines, which identify specific populations that are ineligible for use.

Populations Not Eligible (Contraindicated)

The medicine is contraindicated in patients with conditions that pose an immediate risk, including significant respiratory depression, acute or severe bronchial asthma, and any known or suspected gastrointestinal obstruction such as paralytic ileus. Use is also prohibited for patients concurrently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation. It is also contraindicated in premature infants.

Age and Condition Restrictions

Eligibility is restricted based on Age and Organ Function. For the general pediatric population, safety and effectiveness are often not established, while the use in the elderly requires cautious dose selection. Patients with severe renal or hepatic impairment require close monitoring and often need reduced dosages due to altered drug clearance. Caution is mandatory for patients with a history of substance abuse or those with increased intracranial pressure. During pregnancy, prolonged use carries a documented risk of Neonatal Opioid Withdrawal Syndrome, and long-term use is generally not recommended while breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines specific, clinically significant interactions for morphine, which are classified by the potential outcome when co-administered with other substances. The profile is primarily characterized by severe pharmacodynamic reinforcement effects.

Key Interaction Classifications

The co-administration of Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of severe, unpredictable reactions, and a minimum 14-day separation period is required after discontinuing an MAOI before starting this medicine.

Central Nervous System (CNS) Depressants (including benzodiazepines, sedatives, and general anesthetics) pose a serious interaction risk. Co-administration may lead to profound sedation, respiratory depression, coma, and death due to an additive pharmacodynamic effect. Alcohol (Ethanol) is classified as a CNS depressant and increases the risk of these severe outcomes.

Exposure and Other Effects

Certain substances affect the body's processing of morphine. P-glycoprotein (P-gp) Inhibitors (e.g., Quinidine) may increase the drug’s systemic exposure (plasma concentration) via transporter-mediated inhibition. The combination with Serotonergic Drugs is documented as having the risk of Serotonin Syndrome. Use with Mixed Agonist/Antagonist Opioid Analgesics may result in a reduction in analgesic effect or the precipitation of withdrawal symptoms.

Advertisements

Mechanism of Action

How Morphinum Hydrochloricum Teva Works

Morphinum Hydrochloricum Teva, containing morphine, acts as a full agonist primarily at the boldsymbolmu-opioid receptor ( MOR), engaging a complex molecular cascade that modulates critical signaling pathways across the body. The action involves altering signal transduction within the central and peripheral nervous systems.


Molecular Blockade of Synaptic Transmission

This mechanism targets inhibitory Gi/Go G-proteins coupled to the mu-receptor, which initiates a cascade that fundamentally changes the membrane potential of neurons. Specifically, the action closes presynaptic Ca^2+ channels, thereby halting the release of excitatory neurotransmitters, while simultaneously opening postsynaptic K^+ channels to hyperpolarize the cell. This modulation of ion flux reduces the capacity for signal transmission, suppressing signal propagation in the central nervous system.


️ Systemic Modulation of Involuntary Pathways

The mu-receptor agonism extends beyond sensory pathways to influence regulatory centers responsible for involuntary physiological functions. In the brainstem, this mechanism dampens the responsiveness of the medullary respiratory center to rising carbon dioxide levels, leading to a modified respiratory drive. In the gut, activation of peripheral mu-receptors in the enteric nervous system decreases propulsive smooth muscle contractions. The active metabolite, Morphine-6-Glucuronide ( M6G), also contributes to the total duration and level of receptor engagement.

Advertisements

Dosage and Administration Information

Morphinum Hydrochloricum Teva is administered according to established clinical principles. The medicine is available in several routes of administration, including oral administration using immediate-release (IR) and sustained-release (SR/ER) forms, and parenteral routes such as intravenous (IV), subcutaneous (SC), and intramuscular (IM) injection.

The general usage protocol involves two distinct phases. Treatment often begins with the immediate-release form to determine the patient's stable 24-hour dosage requirement, a process known as titration. The standard adult starting dose for the IR form is typically 10 mg to 30 mg, administered on an as-needed (PRN) basis every four hours.

Once the required dosage is established, the regimen is converted to the sustained-release form for consistent, around-the-clock management. SR/ER tablets are administered on a fixed schedule, typically every 12 hours. A critical administration instruction is that these tablets must be swallowed whole and not crushed, chewed, or dissolved; this practice is necessary to preserve the controlled-release property.

Furthermore, a reduced initial dose is utilized for specific patient populations, including older adults and individuals with renal or hepatic impairment, due to potential alterations in the medicine's clearance. If a dose is missed, patients are instructed to take the next scheduled dose at the regular time and not to double the dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1 and 2 Trials

Early-stage research has explored whether the medication could be used for the treatment of severe pain. The medication is an opioid analgesic, and studies evaluated the biological action by which it interacts with opioid receptors in the central nervous system. Initial Phase 1 studies examined the safety and pharmacokinetics (how the body absorbs, distributes, and eliminates the drug) in healthy volunteers. Phase 2 studies subsequently investigated whether the medication affected symptoms in patients with pain, with participants describing a change in pain scores during the initial treatment period. Pharmacokinetic studies were integral in determining absorption characteristics, which vary depending on the route of administration, such as oral versus injectable forms.


Key Phase 3 Trial Findings

A large, multi-center Phase 3 trial assessed the long-term management of the drug compared to a placebo or other active treatments in participants with severe pain, often cancer-related pain. These trials focused on establishing efficacy and tolerability over extended periods.

  • Pain Relief: Studies evaluated whether the medication affected pain intensity scores compared to a control group, typically using measures like the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS).
  • Quality of Life: Research examined the participants' self-reported quality of life, focusing on its influence on physical functioning and overall well-being.
  • Combination Therapy: Studies investigated whether combining morphine with non-opioid analgesics, such as paracetamol, influenced the total required opioid dose for pain control.

Safety and Tolerability Profile

The trials also focused on the short- and long-term safety profile. Data summarized the observed side effects and long-term tolerability. Commonly reported events in clinical settings and trials include nausea, constipation, and drowsiness. Monitoring for respiratory depression is a critical component of its use. Serious adverse events were reported in accordance with standard medical practice. Ongoing research continues to explore strategies to minimize opioid-related side effects.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Morphinum Hydrochloricum Teva (FAQ)


Q: What are the most common side effects a person can expect from this medicine?

A: According to the official product information, the most common expected side effects are constipation and somnolence (drowsiness), which are classified as very common. Other common reactions include nausea, vomiting, dizziness, and headache. Management strategies for these common effects are typically discussed with the prescribing healthcare professional.


Q: How quickly does the pain relief from Morphinum Hydrochloricum Teva typically begin?

A: For the sustained-release formulation, effects are generally observed starting within a few hours of administration. The immediate-release forms act faster, but a precise onset time is not consistently provided in standard patient materials.


Q: How long does the effect of a dose of this medication generally last?

A: The duration of effect depends on the formulation used. Standard immediate-release forms typically have a duration of action that supports frequent administration. The slow-release forms are designed for longer-lasting pain management and are typically taken once or twice a day (every 12 or 24 hours).


Q: What are the signs of a serious allergic reaction to this medication?

A: Signs of a potentially serious reaction can include hives (urticaria) or a combination of severe symptoms such as confusion, agitation, fever, sweating, tremor, and muscle rigidity. A severe, unusual reaction or signs of serious illness, such as Serotonin Syndrome symptoms, are documented as situations requiring prompt medical evaluation.


Q: What is the main difference between immediate-release and extended-release forms of this drug?

A: The immediate-release forms are fast-acting and short-lasting. Extended-release forms are designed to release the medicine gradually over a longer period, typically 12 to 24 hours, which is intended for stable, around-the-clock chronic pain management.


Q: Is Morphinum Hydrochloricum Teva considered a 'last resort' medication for pain?

A: Official labeling specifies that this medicine is used for the management of severe pain that requires a daily, around-the-clock opioid for an extended period. Official labeling states the medicine is for managing severe pain when non-opioid pain treatments do not provide sufficient relief.


Q: What does the 'Teva' part of the drug name signify?

A: The word Teva refers to the pharmaceutical company that manufactures this specific product. The primary active ingredient, which provides the therapeutic effect, remains morphine hydrochloride.


Q: Why might a person feel dizzy when taking this medicine?

A: Dizziness is listed as a common side effect in regulatory documents. This effect may be related to the drug's action on the central nervous system or its potential to cause hypotension (low blood pressure), which is an uncommon adverse reaction.


Q: What should be done if the pain relief seems to lessen over time?

A: If pain relief lessens, this may be a sign of the body developing tolerance or hyperalgesia (increased sensitivity to pain). Official documents state that when pain relief lessens, dose adjustments or a change in analgesic medication are considerations determined by the prescribing physician.


Q: Can a person operate machinery or drive while taking this medicine?

A: Official guidance notes that due to the potential for drowsiness, dizziness, or slower reactions, the ability to drive or operate heavy machinery may be impaired. It is necessary to clarify safety with a healthcare professional before engaging in these activities.


Q: Why is it important to take a laxative while using this medication regularly?

A: Constipation is a Very Common side effect because the medication slows down movement in the gut. Patient information indicates that management strategies for this expected effect often include increasing fluid intake, dietary fiber, or the use of a laxative.


Q: Can Morphinum Hydrochloricum Teva be used for chronic (long-term) pain, or only acute pain?

A: The sustained-release formulation is approved by regulatory bodies for the management of severe chronic pain that is expected to require continuous, around-the-clock opioid treatment.


Q: What types of over-the-counter medicines or herbal supplements should be noted when taking this drug?

A: Official patient counseling states the importance of discussing the use of non-prescription products, vitamins, or natural health products with a healthcare professional. This is especially important for products that may cause sleepiness, as combining them can have dangerous, additive depressant effects.


Q: Does this medicine have an effect on a person's blood pressure?

A: Yes, regulatory safety documentation lists hypotension (low blood pressure) as an uncommon adverse reaction. This is one of the potential effects of the medicine on the body's cardiovascular system.


Q: Can Morphinum Hydrochloricum Teva cause headaches?

A: Yes, headache is classified as a common adverse reaction in official safety documentation for this type of medication.


Q: Is it true that this drug should not be used for mild pain?

A: Official guidance states that this medication should not be used to relieve mild pain or in situations where non-narcotic medication is expected to be effective. Official guidance states that its use is for severe pain and should be limited to situations where non-narcotic medication is not sufficiently effective.


Q: What steps are needed if the medicine is no longer working as effectively?

A: If the medicine is no longer working as effectively, this may indicate tolerance or hyperalgesia. Regulatory guidance indicates that if the medicine is no longer working effectively, dose adjustments or a change in analgesic medication are factors for the prescribing physician to consider.


Q: What are the risks if a child accidentally ingests Morphinum Hydrochloricum Teva?

A: Official boxed warnings state that accidental ingestion of even one dose, especially by a child, can lead to serious consequences, including the risk of severe respiratory depression and overdose.


Q: Can Morphinum Hydrochloricum Teva cause a patient to feel paranoid or have mental status changes?

A: The medicine may cause mental status changes, including confusion, agitation, and hallucinations, which are known to occur as part of the psychiatric and nervous system side effects. These effects may also be symptoms of a serious condition such as Serotonin Syndrome.

Advertisements

How should Morphinum Hydrochloricum Teva be stored and disposed of?

Storage and Disposal of Morphinum Hydrochloricum Teva

The official requirements for storing and disposing of this medicine are designed to maintain product quality and prevent unauthorized access.

Storage Conditions

  • Temperature and Light: The solution for injection must be stored below 25°C (77°F) and protected from light by being kept in its original outer carton. Store away from excess heat and moisture, and not in a bathroom.
  • Container and Stability: The container should be kept tightly closed. Before use, the solution must be inspected for discoloration or precipitate, and the product must be discarded if either is present.
  • Child Safety: All forms must be stored out of the sight and reach of children and in a secure, inaccessible location to prevent accidental ingestion or misuse.

Disposal Instructions

  • The injection solution is for single use only, and any unused portion must be discarded.
  • Dispose of any unused or expired medication through a medicine take-back program.
  • Local regulations govern the final disposal of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Morphinum Hydrochloricum Teva found in:

A-Z Index: